Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.
3SBio Inc. (SSRX US) advanced 18 percent, the most since November 2007, to $14.19. The Chinese biotechnology company posted fourth-quarter earnings excluding some items that beat the average analyst estimate by 16 percent, according to data compiled by Bloomberg.
Body Central Corp. (BODY US) fell 6.8 percent, the most since Aug. 16, to $26.75. The women’s clothing retailer forecast 2012 revenue of $348 million at most, falling short of the average analyst estimate of $355 million in a Bloomberg survey.
Cooper Cos. (COO US) rose 3.8 percent to $81.96, the highest price since Sept. 20. The maker of contact lenses reported first-quarter earnings of $1.12 a share, beating the average analyst estimate of $1.04.
DR Horton Inc. (DHI US) climbed 6.4 percent, the second-biggest jump in the Standard & Poor’s 500 Index, to $15.49. The largest U.S. homebuilder by volume was lifted to outperform from neutral at Credit Suisse Group AG, which cited increased buyer traffic in a monthly survey of real estate agents. An outperform rating means the stock’s returns are expected to exceed its benchmark’s by at least 10 percent in the next year.
Dynegy Inc. (DYN US) slumped 36 percent, the biggest drop in the Russell 2000 Index, to 76 cents. The independent power producer’s transfer of coal-fired power plants from a unit it later put into bankruptcy was fraudulent and harmed creditors, a court-ordered investigation found.
Green Mountain Coffee Roasters Inc. (GMCR US) plunged 16 percent, the most in the Russell 1000 Index, to $52.59. Starbucks Corp. (SBUX US) said it plans to start selling a single-cup coffee system in a bid to expand beyond its partnership with the Waterbury, Vermont-based specialty coffee and coffee maker company. Starbucks rose 2.9 percent to $51.84.
Heckmann Corp. (HEK US) decreased 9.6 percent, the most since May 2009, to $4.78. The provider of water treatment and disposal services reported fourth-quarter revenue of $51.7 million, missing the average analyst estimate of $54.5 million. The company also said it will acquire Thermo Fluids Inc. for $245 million in cash and stock.
Molycorp Inc. (MCP US) climbed 19 percent, the biggest rally in the Russell 1000 Index, to $30.89. The owner of the largest rare-earth deposit outside of China agreed to buy Canada’s Neo Material Technologies Inc. (NEMFF US) for about C$1.3 billion ($1.3 billion) to increase Chinese sales and gain technology used to make magnets.
Neo Material rallied 37 percent to $11.03.
Pall Corp. (PLL US) fell 3.1 percent, the most in the Standard & Poor’s 500 Index, to $59.30. The supplier of filters for drugmakers and refineries was cut to neutral from outperform by Wedbush Securities, citing softness in markets including China.
Quest Software Inc. (QSFT US) gained 24 percent, the most since 2000, to $24.07. The developer of database-management programs agreed to be taken private by Insight Venture Partners in a deal valuing the company at about $2 billion. Stockholders will get $23 a share.
Smith & Wesson Holding Corp. (SWHC US) surged 23 percent, the most since November 2008, to $6.95. The handgun manufacturer boosted its full-year sales forecast as third-quarter profit beat analysts’ estimates.
Sprint Nextel Corp. (S US) rallied 6.9 percent, the biggest gain in the Standard & Poor’s 500 Index, to $2.78. The request by regulators for Verizon Wireless and cable operators led by Comcast Corp. to provide more data on the companies’ proposed $3.6 billion airwaves deal appears to be “a partial victory” for smaller wireless operators such as Sprint, Stifel Nicolaus & Co. said in a note.
TPC Group Inc. (TPCG US) climbed 9 percent to $41.88, the highest price since July 26. The maker of petrochemical-derived products reported a smaller fourth-quarter loss than analysts estimated.
Zeltiq Aesthetics Inc. (ZLTQ US) rose 18 percent, the most since Oct. 19, to $6.70. The Pleasanton, California-based maker of fat-reduction technology was rated as a new buy by Canaccord Financial Inc. with a 12-month price estimate of $10, citing the non-invasive fat reduction industry as a growth opportunity.
Zogenix Inc. (ZGNX US) fell 18 percent, the most since it went public in November 2010, to $2.03. The specialty pharmaceutical company said 2012 revenue will be $45.5 million to $48.6 million, missing the average analyst estimate of $64.9 million in data compiled by Bloomberg.